Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws

If you purchased or otherwise acquired CBL securities between August 8, 2013 to May 24, 2016, please contact the firm.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) 2/23/16 thru 3/18/16

On March 18, 2016, the Company announced that it had received a Complete Response Letter from the FDA regarding Kangio, stating that it could not approve the drug application for Kangio in its current form and requesting further characterization of bivalirudin-related substances in the drug. On this news, the price of Eagle stock fell $10.18 per share, or almost 19%, from its previous close of $53.68 per share to a close of $43.50 per share – a decline of over 37% from the stock's Class Period high.

If you purchased or otherwise acquired EGRX securities between February 23, 2016 to March 18, 2016, please contact the firm.

Neovasc, Inc. (Nasdaq: NVCN) 1/26/15 thru 5/19/16

On May 19, 2016, news outlets reported that a Massachusetts federal jury had awarded a $70 million verdict to Neovasc's rival, CardiAQ Valve Technologies Inc. ("CardiAQ"), finding that Neovasc had stolen trade secrets from CardiAQ. 

On this news, Neovasc's share price fell $1.38, or 75%, to close at $0.46 on May 20, 2016.

If you purchased or otherwise acquired NVCN securities between January 26, 2015, and May 19, 2016, please contact the firm.

TransEnterix, Inc. (NYSE: TRXC) 2/10/16 thru 5/10/16

On April 20, 2016, the Company issued a press release announcing its receipt of a response from the FDA on its SurgiBot 510(k) submission, which stated that "the FDA has determined that the SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission." On this news, the price of TransEnterix stock fell $2.47 per share, or more than 50%, to close at $2.27 per share on April 21, 2016.

Then on May 20, 2016, the Company issued a press release stating that it "expect[ed] to have further discussion with the FDA, but currently believes that a new 510(k) submission would be required to obtain clearance," that it was reprioritizing its near-term regulatory efforts to focus on another submission, and that, as a result, it "ha[d] taken actions to reduce headcount and investment related to the SurgiBot." On this news, the price of TransEnterix common stock fell another 10% to close at $1.84 per share on May 11, 2016.

If you purchased or otherwise acquired TransEnterix securities between February 10, 2016 to May 10, 2016, please contact the firm.

If you would like to learn more about the investigation of these companies, would like to learn more about any potential claims or you wish to discuss these matters and have any questions concerning this announcement or your rights, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or to sign up online, visit the firm's website at www.henzellaw.com. 

The Law Offices of Marc S. Henzel is a national shareholder litigation firm representing shareholders & investors in various areas of securities laws including but not limited to: class actions, derivatives, transactional (buyouts/takeovers/mergers) and FINRA & NYSE Arbitrations.

Contact:
Law Offices of Marc S. Henzel
Marc S. Henzel
Email: Mhenzel@Henzellaw.com 
Phone 610-660-8000
Website: www.henzellaw.com

LAW OFFICES OF MARC S. HENZEL
MERION STATION, PA 19066

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/law-offices-of-marc-s-henzel-announces-investigation-of-companies-for-violations-of-the-federal-securities-laws-300283822.html

SOURCE Law Offices of Marc S. Henzel